The development of activatable lytic peptides for targeting triple negative breast cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Therapeutics

Background:

• Cytolytic peptides are a novel class of cancer therapeutics.
• They eliminate cancer cells by disrupting cell membranes, offering an alternative to traditional treatments.
• Systemic administration of lytic peptides is limited by nonspecific toxicity.

Purpose of the Study:

• To develop activatable, masked lytic peptides to improve cancer targeting.
• To reduce nonspecific toxicity associated with lytic peptide administration.
• To investigate the selective activation of peptides in triple-negative breast cancer cells.

Main Methods:

• Conjugation of lytic peptides with anionic peptides via a matrix metalloproteinase-sensitive linker.
• Design of activatable peptides using D-amino acids and Aib (α-aminoisobutyric acid).
• Testing peptide activation in MDA-MB-231 triple-negative breast cancer cell line.

Main Results:

• The activatable peptide design demonstrated selective cleavage of the linker in the presence of matrix metalloproteinases.
• Activation occurred specifically within the MDA-MB-231 cell line, which overexpresses these enzymes.
• The masked peptide approach shows potential for targeted delivery.

Conclusions:

• Activatable, masked lytic peptides can be selectively cleaved by cancer-specific enzymes.
• This strategy holds promise for enhancing the targeting ability of lytic peptides in cancer therapy.
• The findings suggest a potential method to mitigate nonspecific toxicity of lytic peptides.